Vicapsys Life Sciences amends patent license with Massachusetts General Hospital, adding new patent rights

Vicapsys Life Sciences, Inc.

Ninth Amendment adds Patent Rights MGH 24644 (PCT/US2018/051950) to exclusive license.
Company must submit a research and development plan for new patent rights within one year.
Company pays $2,000 non-refundable license fee and reimburses $3,956 in patent costs by July 31, 2023.
Amendment updates diligence requirements under Section 3.1 of the original 2013 agreement.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Vicapsys Life Sciences, Inc. amended Ninth Amendment to the Exclusive Patent License Agreement with The General Hospital Corporation d/b/a Massachusetts General Hospital (effective 2023-03-31).

Action: amendment
Agreement: license
Counterparty: The General Hospital Corporation d/b/a Massachusetts General Hospital
Effective: 2023-03-31

Exact text from the filing

On March 31, 2023, Vicapsys Life Sciences, Inc.(the “Company”) and The General Hospital Corporation d/b/a Massachusetts General Hospital (the “Hospital”) entered into a Ninth Amendment to the Exclusive Patent License Agreement (the “Ninth Amendment”).

View on SEC.gov

Browse all material agreements →

Vicapsys Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-019905

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.